Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Cash & Equivalents (2023 - 2025)

Bioharvest Sciences has reported Cash & Equivalents over the past 3 years, most recently at $23.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 863.39% year-over-year to $23.0 million; the TTM value through Dec 2025 reached $23.0 million, up 863.39%, while the annual FY2025 figure was $23.0 million, 863.39% up from the prior year.
  • Cash & Equivalents was $23.0 million for Q4 2025 at Bioharvest Sciences, up from $2.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $23.0 million in Q4 2025 and bottomed at $1.7 million in Q2 2023.
  • The 3-year median for Cash & Equivalents is $3.4 million (2025), against an average of $5.3 million.
  • Year-over-year, Cash & Equivalents plummeted 55.37% in 2024 and then soared 863.39% in 2025.
  • Over 3 years, Cash & Equivalents stood at $5.4 million in 2023, then plummeted by 55.37% to $2.4 million in 2024, then soared by 863.39% to $23.0 million in 2025.
  • The last three reported values for Cash & Equivalents were $23.0 million (Q4 2025), $2.4 million (Q3 2025), and $2.4 million (Q2 2025) per Business Quant data.